MEDIA, Pennsylvania, April 29 -- The Pennsylvania State University Brandywine Campus issued the following news: * * * Brandywine students attend and speak at math conference By Christina Billie MEDIA, Pa. - Penn State Brandywine students who are members of the Math Club recently attended and spoke at a math conference in Mechanicsburg, Pennsylvania, using the opportunity to expand both their knowledge of the field and their networking skills. The Spring Meeting of the Eastern Pennsylvania a more PR

WILMINGTON, Delaware, May 3 -- AstraZeneca, a biopharmaceutical company, issued the following news release: * * * BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca's fixed-dose triple-combination therapy BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6ug)) met all primary endpoints, demonstrating a st more PR

WILMINGTON, Delaware, April 30 -- DuPont issued the following news release: * * * DuPont Announces Regular Quarterly Dividend on Common Stock WILMINGTON, Del., April 29, 2025 - DuPont (NYSE: DD) today announced that its Board of Directors has declared a quarterly dividend of forty-one cents ($0.41) per share on the outstanding Common Stock of the Company (par value $0.01 per share) payable on June 16, 2025, to holders of record of said stock at the close of business on May 30, 2025. About D more PR

HARRISBURG, Pennsylvania, April 30 -- Pennsylvania Auditor General Timothy DeFoor issued the following news release on April 29, 2025: * * * Auditor General DeFoor Releases Tobacco Settlement Fund Audits for 34 Health Care Facilities in 18 Counties HARRISBURG - Auditor General Timothy L. DeFoor today announced the release of tobacco settlement fund audits for 34 health care facilities in Allegheny, Beaver, Berks, Bucks, Cambria, Chester, Clearfield, Dauphin, Delaware, Erie, Lackawanna, Lawren more PR

WILMINGTON, Delaware, April 30 -- AstraZeneca, a biopharmaceutical company, issued the following news release: * * * Update on CAPItello-280 Phase III trial of TRUQAP (capivasertib) in metastatic castration-resistant prostate cancer AstraZeneca is discontinuing the CAPItello-280 Phase III trial evaluating the efficacy and safety of TRUQAP (capivasertib) in combination with docetaxel and androgen-deprivation therapy (ADT) compared to docetaxel and ADT with placebo in patients with metastatic c more PR